Assessing Medication Adherence to Tadalafil 5 mg Once Daily in Erectile Dysfunction: A Cross-Sectional Analysis
Abstract
Our study aimed to examine medication adherence (MA) to tadalafil 5 mg once daily (OaD) in patients undergoing treatment for erectile dysfunction (ED) and to identify factors contributing to potential drug noncompliance. This cross‐sectional study included 233 patients diagnosed with ED. Sociodemographic and clinical data were recorded. MA was assessed using the Medication Adherence Report Scale (MARS). Additionally, the Brief Illness Perception Questionnaire (B‐IPQ), the Beliefs about Medicines Questionnaire (BMQ), and the International Index of Erectile Function (IIEF) were employed to evaluate patients' perceptions and beliefs regarding their condition and treatment. The influence of these factors on MA was thoroughly analyzed. High MA was reported in 136 (58.4%) of 233 patients. Factors, such as education level, monthly income, frequency of medical examinations, smoking habits, and a history of radical pelvic surgery, were found to influence MA (p < 0.05) significantly. Multivariate analysis identified monthly income and radical pelvic surgery history as statistically significant predictors of adherence (p ≤ 0.05). Additionally, adherence was significantly associated with IIEF scores, five items on the B‐IPQ, and the BMQ subscales, including specific concerns, necessity, and general harm (p < 0.05). Tadalafil OaD demonstrates acceptable rates of MA in the treatment of ED. Socioeconomic and clinical factors, patients' cognitive and sensory status, and perceptions…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 233 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.